Close Menu

biomarker detection

NEW YORK (GenomeWeb News) – Cancer care firm N-of-One today announced a deal with Foundation Medicine to translate sequencing data into clinically relevant information.

While using stem cells allows Stemina to "make the tissue type of interest. It's an all-human system," and allows the firm to build "the best potential in vitro environment to study a particular question," its CEO said.

The Waltham, Mass.-based biomarker-detection company ceased operations and filed for Chapter 7 bankruptcy last month.

Pages

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.